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Abstract 
Background: Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer (BBC). 
BBC has no targeted therapies, making the need for mechanistic insight urgent. Reducing adiposity in adulthood can 
lower incidence of BBC in humans. Thus, this study investigated whether a dietary intervention to reduce adiposity 
prior to tumor onset would reverse HFD-induced BBC.
Methods: Adult C3(1)-Tag mice were fed a low or high fat diet (LFD, HFD), and an obese group initially exposed to 
HFD was then switched to LFD to induce weight loss. A subset of mice was sacrificed prior to average tumor latency 
to examine unaffected mammary gland. Latency, tumor burden and progression was evaluated for effect of diet 
exposure. Physiologic, histology and proteomic analysis was undertaken to determine mechanisms regulating obesity 
and weight loss in BBC risk. Statistical analysis included Kaplan–Meier and log rank analysis to investigate latency. 
Student’s t tests or ANOVA compared variables.
Results: Mice that lost weight displayed significantly delayed latency compared to mice fed HFD, with latency match-
ing those on LFD. Plasma leptin concentrations significantly increased with adiposity, were reduced to control levels with 
weight loss, and negatively correlated with tumor latency. HFD increased atypical ductal hyperplasia and ductal carci-
noma in situ in mammary gland isolated prior to mean latency—a phenomenon that was lost in mice induced to lose 
weight. Importantly, kinome analysis revealed that weight loss reversed HFD-upregulated activity of PKC-α, PKD1, PKA, 
and MEK3 and increased AMPKα activity in unaffected mammary glands isolated prior to tumor latency.
Conclusions: Weight loss prior to tumor onset protected against the effects of HFD on latency and pre-neoplastic 
lesions including atypical ductal hyperplasia and DCIS. Using innovative kinomics, multiple kinases upstream of MAPK/
P38α were demonstrated to be activated by HFD-induced weight gain and reversed with weight loss, providing novel 
targets in obesity-associated BBC. Thus, the HFD-exposed microenvironment that promoted early tumor onset was repro-
grammed by weight loss and the restoration of a lean phenotype. Our work contributes to an understanding of underly-
ing mechanisms associated with tumor and normal mammary changes that occur with weight loss.
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Background
Being overweight or obese contributes to ~20  % of US 
female cancer deaths, with breast cancer being the most 
common malignancy and second leading cause of cancer 
death in females [1–8]. Obese women have a higher risk 
of invasive breast cancer, developing distant metastasis, 
recurrence, and mortality [9–14]. Basal-like breast can-
cers (BBCs) are a subset of triple negative breast can-
cers (TNBC) that are highly proliferative and metastatic, 
resulting in poor overall survival [15–17]. Receptor-
specific targeted therapies are currently unavailable for 
TNBC, emphasizing the need for innovative approaches 
for these highly aggressive subtypes [18]. The role of 
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obesity in BBC is well-established through epidemiologic 
[17, 19] and experimental findings from our lab and oth-
ers [20–23], although the underlying mechanisms con-
necting obesity with BBC occurrence are unknown. The 
WHO reported that body weight and physical inactiv-
ity account for at least 20 % of several of the most com-
mon cancers including breast cancer, and posit that more 
than a third of cancers could be avoided by maintaining a 
healthy life style. Millikan et al. indicated that up to 68 % 
of BBC could be prevented by promoting breastfeeding 
and reducing abdominal adiposity [16]. Therefore, weight 
loss may have a protective effect on BBC tumorigenesis 
or tumor progression.
Understanding the reversibility and molecular under-
pinnings of obesity-induced risk in BBC is necessary to 
design prevention and treatment strategies. In addition 
to complex systemic changes associated with obesity, 
it is possible that alterations to the microenvironment 
surrounding a pre-cancerous lesion or tumor account 
for additional obesity-driven regulators of cancer pro-
gression [24, 25]. The cellular composition, metabolites, 
kinases, growth factors including adipokines such as lep-
tin, and modifications to the extracellular matrix in the 
microenvironment have critical effects on tumor biol-
ogy [22, 26]. Alterations to the microenvironment may 
contribute to the conversion of normal epithelial cells 
to hyperplastic cells and/or drive the progression from 
atypical hyperplasia to carcinoma [27]. The window of 
dietary exposures, including weight gain and weight loss, 
is another important variable to consider in breast can-
cer risk. Epidemiological studies have shown that weight 
gain in adult life specifically is associated with increased 
breast cancer risk [28, 29]. Thus, we hypothesized that 
early adulthood HFD-induced carcinogenic effects on 
BBC can be reversed through weight loss and are depend-
ent upon the changes in the microenvironment of mam-
mary glands before tumor onset. To test our hypotheses, 
we used C3(1)-Tag GEMMs, which have been previously 
shown to be a faithful preclinical model of human BBC 
by our lab and others [20, 21, 30, 31]. Herein, we dem-
onstrate that HFD-accelerated latency was delayed by 
weight loss that was induced by switching from HFD 
to LFD. Diet regulated changes to the mammary gland 
microenvironment included significantly increased 
atypical ductal hyperplasia (ADH) and ductal carci-
noma in situ (DCIS) before tumor onset. Weight loss and 
reduction of adiposity associated with diet switch suc-
cessfully reversed ADH and DCIS to the levels detected 
in lean mice. To determine specific pathways regulated by 
weight loss, unaffected mammary glands isolated prior to 
average latency were subjected to activated kinome pro-
filing. Relative to HFD-induced kinase changes, weight 
loss-induced regulation included significantly reduced 
activity of PKC-α, PKD1, PKA, and MEK3 in unaffected 
mammary glands, which together result in inactivation of 
the mitogen-activated protein kinase (MAPK) pathway 
associated with proliferation. Weight loss after weight 
gain also increased the activity of metabolically sensitive 
kinases such as 5′-AMP-activated protein kinase AMPK 
which can also inhibit proliferative capacity. Our findings 
suggest that HFD altered the mammary gland prior to 
frank tumor onset, which contributed to ADH, DCIS and 
tumor latency, and these changes were limited by weight 
loss.
Results
Tumor latency shortened by HFD exposure could be 
delayed by weight loss prior to tumor onset
To determine if weight loss in mice fed HFD prior to 
tumor onset would alter the course of tumorigenesis and/
or progression, mice were subjected to various diet expo-
sures (Fig.  1a). At 8  weeks of age, C3(1)-Tag mice were 
fed control 10 % LFD (N = 28) or 60 % HFD (N = 59). 
There were no significant differences in body weight 
before starting the diet study (8  weeks of age, Fig.  1b). 
Mice on 60  % diet gained more weight than those on 
control 10  % diet, and were significantly different after 
1 week on diet (P < 0.01) and remained significantly dif-
ferent until the end of the study (Fig. 1b). At 11 weeks of 
age, N = 28 mice on the 60 % diet were switched to 10 % 
diet to induce weight loss (60–10  % group, Fig.  1a). At 
week 13 (1 week post diet switch), mice on 60–10 % diet 
lost weight to the level of 10  %-fed mice, and remained 
lean, identical to 10 %-fed mice for the remainder of the 
study. Mice from 60 to 10 % diet group weighed signifi-
cantly less compared to mice on 60 % diet from week 13 
to the end of study (P < 0.0001, Fig. 1b).
Time to first tumor was detected as tumor latency. A 
log-rank test was performed and Chi square was equal to 
6.73, with 2 degrees of freedom. Hazard ratios compar-
ing 60 to 10  % was 0.51 (P  <  0.01), 60 to 60–10  % was 
1.96, and 10 to 60–10 % was 0.87 (Fig. 1c). Mice exposed 
to 60  % diet exhibited a significant decrease in median 
tumor latency compared with lean controls (10 %), from 
a median of 17.6 weeks in 10 %-fed mice to 15.9 weeks 
in 60 %-fed mice (P < 0.01, Fig. 1c). Mean latencies were 
17.6, 16.1 and 17.2 weeks for mice in 10, 60 and 60–10 % 
diet groups, respectively (P < 0.05). Mice that first gained 
weight and then lost weight after diet switch had signifi-
cantly delayed tumor latency of 17.1 weeks compared to 
60 %-fed mice (P < 0.01, Fig. 1c). No significant difference 
in median or mean tumor latency was found between 
mice on 10  % diet and on 60–10  % diet. There was no 
change in total tumor burden (Additional file  1a). Fur-
thermore, no difference was found in the tumor volumes 
at different time points (Additional file 1a).
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Early adulthood HFD-induced changes in body compo-
sition are rapidly reversed by weight loss. Although the 
mice only gained a few grams on the 60 % HFD, which is 
typical for FVB/N and C3(1)-Tag mice [20, 21, 32], there 
was a significant effect of diet exposure and diet switch 
on body composition. Mice fed the 60  % diet gained 
body fat in the first 3 weeks (from 8 to 11 weeks of age) 
as determined by MRI (Fig. 2a). Mice fed 60 % diet had 
significantly greater body fat mass compared to the mice 
on 10 % diet at 11 weeks of age (P < 0.0001, Fig. 2a). At 
13 weeks of age (2 weeks after diet switch), body fat con-
tent of mice on the 60–10 % diet decreased significantly, 
and remained similar to 10  % fed mice until sacrifice. 
Mice on 60  % diet exhibited greater body fat content 
compared to 10 % and 60–10 % fed mice from 13 weeks 
of age until sacrifice (P < 0.0001 at weeks 13 and 15, and 
at sacrifice; Fig. 2a). There were no significant differences 
in absolute lean mass in grams in any of the diet groups 
tested (data not shown). In line with changes in adiposity, 
plasma concentrations of the adipokine leptin increased 
significantly in mice fed the 60 % diet compared to mice 
fed 10 % diet after 3 weeks on diet (P < 0.0001, Fig. 2b). 
After diet switch from 60 to 10 % diet, leptin concentra-
tions of mice in the 60–10  % group were significantly 
reduced to the concentrations in lean mice (P < 0.0001, 
60–10 % vs. 60 %; Fig. 2b), consistent with adiposity and 
body weights. No significant difference in leptin was 
found between 10 and 60–10  % groups. The 60  %-fed 
group had significantly greater leptin concentrations 
than the other 2 groups as soon as 2 weeks after the diet 
switch and at sacrifice (P < 0.0001, 60–10% vs. 60% and 
10 vs. 60 %, Fig. 2b). No correlation of plasma leptin con-
centration and tumor latency was found before diet start 
at 8 weeks of age (data not shown). However, at 11 and 
Fig. 1 Weight loss protected against HFD-mediated early BBC onset. a Model of study design 1. At 8 weeks of age, C3(1)-Tag mice were randomly 
assigned to 10 % (N = 28) and 60 % (N = 59) diet groups. After 3 weeks on diet, at 11 weeks of age, N = 28 mice on 60 % were switched to 10 % 
diet. Mice were monitored for tumor onset by palpation 3 times a week. Three weeks after tumor onset, mice were sacrificed. b Body weight was 
measured weekly. 10 % vs. 60–10 % (^P < 0.05); 10 % vs. 60 % (*P < 0.01); and 60 % vs. 60–10 % (#P < 0.0001). c Mice were tumor free until first tumor 
palpated (P < 0.01, 10 % vs. 60 %; 60–10 % vs. 60 %)
Page 4 of 13Qin et al. Cancer Cell Int  (2016) 16:26 
13  weeks of age (P  =  0.017, 0.0043, respectively, data 
not shown) and at sacrifice, plasma leptin concentration 
negatively and significantly correlated with tumor latency 
(P = 0.0029, Fig. 2c). There were no diet-induced changes 
in 6-h fasting blood glucose levels (Additional file 2a) or 
plasma insulin (Additional file 2b) over the course of the 
study. Likewise, HOMAIR, a proxy measure of insulin 
resistance, did not reveal significant diet effects (Addi-
tional file 2c).
HFD and weight loss affected pre-neoplastic lesions in 
the microenvironment of unaffected mammary glands. 
Since HFD exposure and weight loss significantly altered 
tumor latency in this GEMM that is already transgeni-
cally induced, we next sought to examine alterations in 
the microenvironment of mammary glands prior to pal-
pation of tumor or latency. Mice were placed on diets 
at 8 weeks of age, and diet switch occurred at 11 weeks 
of age, as above, however all mice were sacrificed at 
15 weeks of age to examine unaffected mammary glands 
where no tumor was palpated (Fig.  3a). C3(1)-Tag mice 
develop tumors due to T antigen (Tag) under the control 
of the rat prostatic steroid binding protein C3(1) gene 
[33]. It is well-established that at 8  weeks old, C3(1)-
Tag mice develop ADH [33]. At 12  weeks of age, DCIS 
appears, and at 16–18  weeks of age on average, female 
mice develop tumors when DCIS becomes IDC [33]. 
Using a well-defined model allowed for us to test for spe-
cific alterations to the mammary gland associated with 
diet exposure. First, we examined if initiation of diet at 
8  weeks of age altered the number of cells expressing 
the SV40 Tag transgene which could regulate latency. 
Tag immunohistochemical analysis exhibited no sig-
nificant changes in unaffected mammary glands of mice 
(quantification in Fig.  3b and representative images in 
Fig. 2 Body composition predicts latency. a MRI was used to evaluate body composition. 10 vs. 60 % (#P < 0.0001); 60 % vs. 60–10 % (^P < 0.0001); 
and 10 % vs. 60–10 % (*P < 0.0001). N = 28 10 %, N = 31 60 %; N = 28 60–10 %. b Plasma leptin was quantified. 10 % vs. 60 % (#P < 0.0001); 60 % vs. 
60–10 % (^P < 0.0001); 10 % vs. 60–10 % (*P < 0.0001). N = 12 10 %, N = 12 60 %; N = 13 60–10 %. c Spearman correlations of plasma leptin with 
latency at sacrifice (P = 0.0029). N = 12 10 %, N = 12 60 %; N = 13 60–10 %
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Fig.  3c–e). Secondly, we determined if HFD exposure 
and diet-induced weight loss altered pre-cancerous lesion 
formation. Histopathologic analysis of unaffected mam-
mary glands was examined for regions including ADH, 
DCIS, and IDC (Fig. 4a–d). C3(1)-Tag mice fed the 60 % 
diet had significantly increased ADH in unaffected mam-
mary glands at 15 weeks of age (P < 0.05, Fig. 4e). Dietary 
intervention-induced weight loss significantly decreased 
ADH to the levels detected in mammary glands from 
lean mice on 10 % diet (P < 0.05, 60 vs. 60–10 %, Fig. 4e). 
HFD exposure increased DCIS by about threefold; 
interestingly, weight loss significantly decreased DCIS 
(P  <  0.05, 60 vs. 60–10  %, Fig.  4f ). Although mammary 
glands from mice fed 60 % diet had increased numbers of 
IDC in unaffected mammary glands compared to 10 and 
60–10  %-fed mice, no statistical differences were found 
between diet exposures (Fig. 4g).
MIB/MS kinome analysis revealed dramatic regula-
tion of kinases by HFD and diet-induced weight loss. 
Global analysis of kinase activity in unaffected mam-
mary glands was carried out using multiplexed inhibitor 
beads (MIBs), which consist of mixtures of Sepharose 
beads covalently bound to various linker adapted, type I 
pan-kinase inhibitors. MIBs have been shown to prefer-
entially capture kinases in their active conformation to 
reproducibly measure global dynamic changes in kinase 
activity [34–36] (Fig. 5a). MIBs have been previously vali-
dated using Western immunoblot and kinase assays in 
breast cancer cell lines and patient samples [34]. Using 
MIBs and subsequent mass spectrometry (MIB/MS) anal-
ysis, we identified a total of 155 kinases from unaffected 
mammary glands of C3(1)-Tag mice at 15  weeks of age 
(Additional file 3). Individual runs of 2–4 pooled samples 
in each run are displayed by kinase family for 60  %-fed 
mice (Additional file  3a) and 60–10  %-fed mice (Addi-
tional file 3b), both groups were normalized to 10 %-fed 
controls. Means of the runs for the 60 and 60–10 %-fed 
mice are displayed (Additional file 3c). Additional file 4a 
shows a kinase signature defining a reprogrammed 
kinome in response to HFD-induced changes to the mam-
mary gland microenvironment prior to average tumor 
latency. Six kinases displayed increased activity by >1.5 
fold when normalized to control mice on 10 % diet, while 
the activity of four kinases were decreased to <0.5 fold of 
kinases activity detected in mammary glands from mice 
fed 10 % diet (Additional file 4a). The six kinases elevated 
Fig. 3 Diet did not affect tumor initiation. a Model of study 2. A second set of mice were started on 10 % (N = 8) and 60 % (N = 20) at 8 weeks of 
age. At 11 weeks of age, N = 11 of 60 %-fed were switched to 10 % as in study design 1. Mice were sacrificed at 15 weeks of age prior to average 
tumor latency and unaffected mammary glands were isolated. b T antigen (Tag) expression was measured in unaffected mammary glands by 
immunohistochemical staining. c–e Representative 40X images are shown of Tag IHC staining from c 10 % diet group, d 60 % diet group, and e 
60–10 % diet group
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by HFD included protein kinase C alpha type (KPCA, 
Prkca), bone morphogenetic protein-2-inducible pro-
tein kinase (BMP2  K, Bmp2  K), phosphatidylinositol 
3-kinase catalytic subunit type 3 (PK3C3, Pik3c3), serine/
threonine-protein kinase D1 (KPCD1, Prkd1), serine/
threonine-protein kinase MARK1 (MARK1, mark1), and 
mast/stem cell growth factor receptor Kit (KIT, Kit). The 
4 kinases decreased by HFD included 5′-AMP-activated 
protein kinase catalytic subunit alpha-2 (AAPK2, Prkaa2), 
interleukin-1 receptor-associated kinase 1 (IRAK1, Irak1), 
fructosamine-3-kinase (FN3 K, Fn3 k), and epithelial dis-
coidin domain-containing receptor 1 (DDR1, Ddr1) in 
unaffected mammary glands (Additional file 4a).
Weight loss resulted in decreased expression of all 
kinases that were elevated in HFD-fed mice, since no 
kinases in the diet switch group increased more than 
1.5 fold when normalized to mice on 10  % diet (Addi-
tional file  3b). Fourteen kinases from the diet switch 
group showed more than a 1.25-fold increase in activity 
when normalized to mice on 10 % diet. In the diet-switch 
group, five kinases decreased to more than 0.5 fold of the 
10 % diet mice (Additional file 4b).
When directly comparing activity of kinases from unaf-
fected mammary glands isolated from mice on HFD 
versus diet switch groups, several important kinases 
were discovered to be regulated by HFD and inversely 
regulated by weight loss (Fig. 5b). Five kinases that were 
elevated by HFD feeding and decreased by weight loss 
included KPCA (Prkca), serine/threonine-protein kinase 
D1 KPCD1 (Prkd1), dual specificity mitogen-activated 
Fig. 4 Pathological changes in the unaffected mammary gland induced by HFD were reversed by weight loss. Unaffected mammary glands were 
collected from 15-week old C3(1)-Tag mice in study 2. a–d. Representative 40X images are shown of a normal duct, b ADH, c DCIS, and d IDC. e 
Areas of ADH were quantified in N = 6, 40X regions per section per mouse. *P < 0.05, 10 % vs. 60 %; 60–10 % vs. 60 %. f Areas of DCIS were quanti-
fied as in e *P < 0.05, 60–10 % vs. 60 %. g Areas of IDC were quantified as in e N = 8 10 %; N = 9, 60 %; N = 11, 60–10 %
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protein kinase kinase 3 (MP2K3) MEK3 (Map2k3, 
P = 0.0044), PKA (Prkacb, P = 0.0035), and unc-51 like 
kinase 3 ULK3 (Ulk3, P = 0.034). In contrast, two kinases 
were unchanged or reduced by weight gain and signifi-
cantly increased by weight loss, respectively, including 
adenosine kinase ADK (Adk, P  =  0.045) and 5′-AMP-
activated protein kinase catalytic subunit alpha-2 
(AAPK2/AMPK (Prkaa2, P = 0.037).
Discussion
One-third of US population is obese and another third is 
overweight [37]. Considering the high prevalence, obesity 
could be a target for breast cancer prevention with effec-
tive intervention strategies including weight loss, dietary 
modification, and/or pharmacological approaches. Epi-
demiologic observations have demonstrated increased 
BBC risk in premenopausal women with high BMI [16, 
38]. BBC is also detected at a high prevalence in African 
Americans, a group more susceptible to both obesity and 
weight retention after pregnancy, a period most likely 
in early adulthood [16]. Indeed, weight loss induced by 
decreased dietary fat intake in early-stage breast cancer 
patients has been shown to improve the rate of relapse-
free survival [39]. In murine studies, groups including 
Fig. 5 Kinome profiling of unaffected mammary glands revealed regulation of PKD1-PKC-α-PKA-MEK3 and AMPK by diet exposure. To profile the 
activated kinome, unaffected mammary glands from mice at 15 weeks of age were collected for multiplexed inhibitor bead (MIB) affinity chro-
matography and mass spectrometry analysis. a MIBs consist of mixtures of Sepharose beads with covalently immobilized, linker-adapted, broad 
pan-kinase inhibitors (listed on left of column) are designed to capture kinases in the active state in a reproducible and reliable assay. Two to four 
samples were pooled into a total of 3 runs per diet group. (N = 8 mice in each diet group). All kinase activity is normalized to 10 %-fed controls. 
b Mean kinase activity is presented to compare kinases in the unaffected mammary glands that were significantly different between mice in the 
60 % group and 60–10 % group. *P < 0.005, ^P < 0.05, 60 % vs. 60–10 %) In b, no error bar is present in pooled samples when kinases were down-
regulated below level of detection and only 1 run detected activity. c, d Protein–protein interactions of significantly altered kinases in unaffected 
mammary gland of mice on 60–10 % diet compared to mice on 60 % diet. c Search Tool for the Retrieval of Interacting Genes/Proteins (STRING ver-
sion 10) was used to visualize known protein–protein interactions between significantly regulated kinases. Confidence view was shown. Stronger 
associations are represented by thicker lines. d Cartoon of a subset of kinases regulated by HFD and reversed by weight loss and the contribution of 
obesity-induced leptin signaling
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Cleary et al. and Hursting et al. have demonstrated that 
weight loss induced through caloric restriction protected 
against the development of mammary tumors [23, 40–
42]. We previously reported that HFD-induced tumor 
progression was reversed by weight loss in a life-long 
diet exposure study [20]. However, no group has focused 
on the adult window of susceptibility, a time when most 
Americans gain weight [37]. Thus, BBC in humans and 
varied murine models is responsive to energetics and 
body composition status, but the mechanisms remain 
unclear.
Herein, we aimed to focus solely on the early adult 
window of susceptibility and modification of risk factors 
that could contribute to tumor progression. C3(1)-Tag 
mice were fed LFD or HFD diets starting at 8  weeks of 
age, which is after pubertal development and is consid-
ered early adulthood in the murine life cycle. Using this 
unique BBC GEMM, we demonstrated that HFD-feeding 
in adulthood drove aggressive tumor formation, which 
resulted in a significant reduction in tumor latency. 
Importantly, weight loss prior to average tumor onset 
significantly delayed tumor latency, reversing the effects 
of HFD. There were no effects on tumor initiation in 
C3(1)-Tag mice as there were no diet-induced differences 
in initiating cells expressing Tag. Therefore, data suggest 
that HFD doesn’t play a dramatic role in the very early 
regulation of tumor initiating cells in C3(1)-Tag mice, but 
rather the progression through hyperplasia to DCIS to 
detectable malignancy.
The normal microenvironment can suppress tumor 
progression, but when the homeostasis is interrupted 
(e.g. by obesity, etc.), the microenvironment can pro-
mote tumor growth [24]. Therefore, histopathologic 
analysis was undertaken on unaffected mammary 
glands isolated from mice at 15  weeks of age before 
frank tumors could be detected by palpation. Analysis 
revealed significantly increased ADH and DCIS after 
just 7  weeks of HFD exposure. Mice that lost weight 
and adiposity secondary to diet switch were signifi-
cantly protected from HFD-induced ADH and DCIS 
development. The number of invasive carcinomas was 
also decreased by weight loss compared to HFD-fed, 
although this reduction was not statistically significant. 
The fact that ADH and DCIS were increased by HFD 
and reversed to the level of lean mice by weight loss 
indicated that adiposity could affect already initiated 
proliferating cells during this unique window of suscep-
tibility (e.g. from initiated cancer stem cells to ADH, or 
from ADH to DCIS, and from DCIS to IDC) [33]. Thus, 
the pathological changes detected in the mammary 
gland at this critical period of tumorigenesis indicated 
that the progression of basal-like tumors can be delayed 
or reversed by HFD and weight loss.
Leptin is a hormone produced by adipocytes in propor-
tion to adiposity. A meta-analysis reported that women 
with breast cancer have elevated plasma leptin levels [43]. 
High leptin receptor mRNA expression in breast cancer 
tissue was also established to predict poor prognosis in 
patients with high serum leptin levels [44]. Leptin may 
drive BBC through maintaining cancer stem-like prop-
erties in orthotopically transplanted mice [45]. Leptin 
signaling also induced breast tumor cell proliferation 
in both human and mouse cell lines [46, 47]. Consider-
ing the crucial role of leptin signaling in breast cancer in 
both mouse and human reports, weight loss-associated 
changes in leptin concentrations could play an important 
role in BBC prevention. Weight gain in early adulthood 
increased circulating leptin concentrations and weight 
loss reversed the leptin levels to those detected in LFD-
fed controls. Other contributors often associated with 
obesity-induced carcinogenesis, including glucose and 
insulin, were not altered by diet exposures.
Nearly half of the all molecularly targeted cancer ther-
apeutics is kinase inhibitors [48]. Using novel kinome 
profiling, our results from unaffected mammary glands 
of mice captured 155 activated kinases from all major 
kinome subfamilies. HFD feeding and weight loss up- or 
down-regulated several kinases that interacted with each 
other (Fig. 5c). Our analysis focused on 7 kinases specifi-
cally reciprocally regulated by HFD and diet-switch. The 
kinase that was most elevated by HFD feeding and dis-
played the greatest decrease in activity after weight loss 
was a serine/threonine protein kinase (KPCA, Prkca), 
known as PKC-α. Importantly, PKC-α is a marker for 
breast cancer aggressiveness [49]. Recent studies have 
identified PKC-α as over-expressed in triple negative 
breast cancer cells expressing stem-like properties [50]. 
Inhibitors targeting PKC-α and cMet, another kinase that 
we reported to be regulated by HFD-induced exposure 
and weight loss [20, 21], decreased triple-negative breast 
tumor growth in murine models [50].
An important upstream regulator of PKC-α was dem-
onstrated to be the second most potently upregulated 
kinase by HFD and dramatically reduced by weight loss, 
the serine/threonine-protein kinase D1 (KPCD1, Prkd1), 
also known as PKD1. PKD1 has been shown to increase 
cell proliferation in breast, prostate, salivary tumors and 
pancreatic cancers [51, 52]. PKD1 also reduced serum- 
and anchorage-dependence for proliferation and survival 
in  vitro and drove tumorigenesis in xenograft models 
of mammary tumors [53]. Borges et  al. demonstrated 
that PKD1 is expressed in cells of the unaffected mam-
mary gland, and is necessary for preventing epithelial-
to-mesenchymal transition and invasive carcinoma [54]. 
Of great relevance to studies presented herein, PKD1 is 
one of the few genes identified as regulator of obesity in 
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human populations. Through genome-wide association 
studies (GWAS), PKD1 was identified as a loci associated 
with human obesity, especially in obesity prevalent young 
adults [55], which is similar to the window of diet expo-
sure and latency in this study. Clearly, PKD1 must be fur-
ther investigated, especially its role in obesity-associated 
breast tumorigenesis. Downstream of PKD1 and PKC-α 
is cAMP-dependent protein kinase catalytic subunit beta 
(KAPCB, Prkacb), also known as PKA. PKA activity was 
also increased by HFD and decreased by weight loss. 
Elevated PKA activity in the mammary epithelium gener-
ated tumors in a murine model and was associated with 
BBC and poorer outcomes in patients [56].
PKD1, PKC-α and PKA all act through the MAPK 
kinase family. The MAP kinase kinase family member the 
dual specificity mitogen-activated protein kinase kinase 
3 (MP2K3, Map2k3), also known as MEK3 or MKK3, 
was also significantly upregulated. MEK3 is increased by 
mutant p53 [57], and led to cell proliferation and survival 
through increased oncogene RAS expression, as well as 
activation of p38α (MAPK14) [58]. Inhibition of MEK3 
led to reduction in cell proliferation and apoptosis [59], 
and knockdown of MEK3 led to reduced cell viability 
as well as increased susceptibility to chemotherapeutic 
agents in  vitro and in  vivo [59]. Interestingly, MEK3 is 
also linked to obesity [60] and lipotoxicity [61] in human 
populations, as well as diabetes in a murine model [62]. 
In sum, Fig.  5d demonstrates how weight loss reversed 
the HFD-induced activation of PKC-α, PKD1, PKA, and 
MEK3 in unaffected mammary glands, which may lead to 
inactivation of MAPK/p38α pathway, resulting in delayed 
tumor latency in mice lost weight compared to mice fed 
HFD.
A final kinase moderately but significantly up-regulated 
by HFD and down-regulated by weight loss was the ser-
ine/threonine protein kinase unc-51 like kinase 3, ULK3 
(Ulk3). ULK3 regulates the developmental and onco-
genic pathway of sonic hedgehog (SHH) signaling and 
autophagy. ULK3 is over-expressed in certain cancer cell 
lines [63]. Since it is significantly reduced with weight 
loss after weight gain, ULK3 may be a promising target.
Two kinases were regulated in the inverse direction: 
these were reduced by HFD and increased with weight 
loss after diet switch. A kinase whose activity was reduced 
with HFD to less than 40  % of lean mice on LFD, and 
then reversed to control levels with weight loss was the 
alpha 2 catalytic subunit of AMP-activated protein kinase 
(AAPK2, Prkaa2) (Fig.  5d). AMPK is an energy-sensing 
kinase that controls nutrient metabolism [64]. Leptin is 
known to inhibit AMPK’s action [65]. Consistent with 
increased activated AMPK by weight loss in our results, 
activation of AMPK has been suggested to be a target for 
cancer prevention and treatment [66]. A low incidence of 
cancers in diabetic patients on metformin is likely due to 
the drug’s anti-proliferative effect through activation of 
AMPK [67]. Breast cancer patients on metformin have 
been found to have a lower proportion of higher stage 
tumors than control patients [68]. Importantly, metformin 
can inhibit cell growth in basal-like cancer cells [69]. 
AMPK merits further study in BBC cancer prevention.
A limitation in the interpretation of our studies is that 
we induced weight loss after HFD exposure using a com-
mon protocol of diet switch. While epidemiologic and 
experimental evidence overwhelmingly support a strong 
role for obesity in breast cancer risk, some reports sug-
gest that HFD exposure alone (in the absence of obesity) 
is enough to alter the mammary microenvironment and 
increase breast cancer risk [22, 70–72]. The most com-
mon HFD used in research is lard-based, which contains 
high levels of saturated fatty acids, known activators of 
the toll like receptor 4 (TLR4) pathway [73–76], a con-
tributor to breast cancer [22]. Thus, in our study design 
it is unknown if diet exposure itself or obesity-associated 
alterations contribute to BBC progression. Future stud-
ies include modification of diet including caloric restric-
tion to determine the contribution of diet alone versus 
changes in adiposity and leptin as reported herein.
Conclusions
One-third of US adults are obese and two-thirds are 
overweight, underscoring a critical need to reduce 
breast cancer risk, especially triple negative breast can-
cers (TNBC) that are significantly associated with obe-
sity. Obesity was recently recognized by the American 
Medical Association as a disease [77] and the American 
Society of Clinical Oncology just published a position 
statement on their recognition of and commitment to 
reducing obesity-associated cancer [78]. Lifestyle com-
ponents, like obesity, play an important role in cancer 
initiation and progression [24]. While biological mod-
els of cancer have traditionally emphasized cell-auton-
omous characteristics, it is clear that changes in the 
microenvironment are also necessary [79]. Herein we 
have identified the adipokine leptin and relevant kinases 
that correlate with tumor latency and pre-neoplastic 
lesion formation in the mammary gland. Future studies 
to further elucidate the molecular links between cells of 
the microenvironment and unique obesity-regulated fac-
tors will be transformative, with significant potential to 
influence obesity prevention or dietary recommendation 
initiatives and may yield biomarkers of risk for future 
study. Improved understanding of biological mecha-
nisms could also yield prevention strategies to address 
racial disparities since BBC is highly prevalent in young, 
African American and Hispanic women, contributing to 
disparities in cancer mortality [19].
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Methods
Reagents. Rat/Mouse Insulin ELISA kit was obtained 
from Millipore (EZRMI-13  K; EMD Millipore, Billerica, 
MA, USA). Anti-SV40-Tag (sc-20800) was obtained 
from Santa Cruz (Santa Cruz, Santa Cruz, CA). Biotin-
SP (longer spacer) AffiniPure Goat anti-Rat IgG was 
from Jackson ImmunoResearch (#112-065-167, Jackson 
ImmunoResearch Inc. West Grove, PA, USA).
Animals and diet
Animal studies were performed with approval and in 
accordance with the guidelines of the Institutional Ani-
mal Care and Use Committee at the University of North 
Carolina at Chapel Hill. Animals were cared for accord-
ing to the recommendations of the Panel on Euthanasia 
of the American Veterinary Medical Association. The 
veterinary care provided at UNC is in compliance with 
the Public Health Service Policy on Humane Care and 
Use of Laboratory Animals and meets the National Insti-
tutes of Health standards as set forth in the Guide for the 
Care and Use of Laboratory Animals (DHHS Publication 
No. (NIH) 85-23 Revised 1985). The animal facility is 
Association for Assessment and Accreditation of Labora-
tory Animal Care (AAALAC) approved and is responsi-
ble for the health and husbandry of animals. UNC also 
accepts as mandatory the PHS Policy on Humane Care 
and Use of Laboratory Animals be Awardee Institutions 
and NIH Principles for the Utilization and Care of Ver-
tebrate Animals Used in Testing, Research, and Train-
ing. During breeding and after weaning at 3  weeks old, 
female C3(1)-Tag mice were put on Prolab Isopro RMH 
3000 from LabDiet (St. Louis, MO, USA) until they were 
8  weeks old when they were started on defined diets. 
Matched defined diets from Research Diets Inc. (New 
Brunswick, NJ, USA) provided 10  % kcal (“10  %”, LFD) 
and 60 % kcal (“60 %”, HFD) derived from fat. Details of 
diet in Sundaram et al. [21]. At 8 weeks of age, mice were 
randomly assigned to LFD 10 % (N = 28) and HFD 60 % 
(N = 59) diet groups. After 3 weeks on diet, at 11 weeks 
of age, N = 28 mice on 60 % were switched to 10 % diet 
(Study 1, Fig.  1a). A second set of mice were similarly 
initiated on 10 % (N = 8) and 60 % (N = 20) at 8 weeks 
of age. At 11  weeks of age, N  =  11 of 60  %-fed were 
switched to 10 % as above. This second cohort was sac-
rificed at 15 weeks of age prior to average tumor latency 
and unaffected mammary glands were isolated (Study 2, 
Fig. 3a).
Tumor latency, number, and progression
Tumor latency was defined as age at detection of first 
tumor in weeks. After detection of the first tumor, 
tumor volumes were monitored weekly over 3  weeks 
using calipers to measure the width (short diame-
ter) and length (long diameter) in millimeter for each 
tumor. The tumor volumes were calculated using the 
formula: length  ×  width2  ×  0.5. The total number of 
tumors per mouse was counted at sacrifice for total 
tumor burden.
Body weight and composition
Body weight was measured prior to starting mice on diet 
and weekly until sacrifice. Body composition including 
lean mass, fat mass, free water content, and total water 
content was also measured at 8 (diet start), 11 (diet 
switch), 13, and 15  weeks of age, as well as at sacrifice 
using quantitative magnetic resonance whole body com-
position analyzer (Echo Medical Systems, Houston, TX, 
USA). Fat mass is presented as percent fat mass over total 
body weight [20, 21].
Metabolic parameters and plasma
Blood glucose was measured on mice fasted for 6  h 
prior to start of diet, at diet switch (3  weeks on diet), 
2  weeks after diet switch, and at sacrifice using a Bayer 
contour blood glucose monitor (Bayer HealthCare LLC, 
Tarrytown, NY, USA). Plasma was collected at differ-
ent time points. Plasma leptin was measured using the 
MILLIPLEX MAP mouse angiogenesis/growth factor 
magnetic bead panel—cancer multiplex assay (EMD Mil-
lipore, Billerica, MA, USA). Plasma insulin concentra-
tions were measured using Rat/Mouse Insulin ELISA kit 
(EZRMI-13 K; EMD Millipore, Billerica, MA, USA). The 
homeostasis model assessment was used to calculate the 
approximate insulin resistance (HOMAIR) using the for-
mula (blood glucose (mg/dl at sacrifice) × plasma insulin 
concentration (ng/ml)/405) [21, 80].
Histological staining
Portions of the unaffected fourth mammary glands iso-
lated from mice at 15  weeks of age in study 2 (Fig.  3a) 
were formalin-fixed and paraffin-embedded for immu-
nohistochemistry (IHC) and H&E staining. Anti-SV40-
Tag (1:250) IHC staining was conducted and analyzed 
as previously described [21, 31, 76]. Briefly slides were 
scanned into the Aperio Scanscope CS system (Aperio 
Technologies, Vista, CA, USA) at a magnification of 
40× and quantified using the Aperio Imagescope soft-
ware. The slides were analyzed using the algorithms as 
described [31]. Random areas from sections (N = 6) were 
quantified and averaged per animal. Microenvironment 
pathological analysis of H&E staining was completed 
by a certified veterinary pathologist (S.M.). Sections of 
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unaffected mammary from study 2 were analyzed for the 
presence of normal ducts, ADH, DCIS, and IDC.
MIB/MS kinome analysis
Multiplexed inhibitor bead (MIB) affinity chromatog-
raphy was completed to measure activated kinases as 
described previously [36]. Briefly, unaffected mam-
mary glands from study 2 were pulverized and lysed 
in MIB lysis buffer, and 1  % of phosphatase inhibitor 
cocktail 2 and 3 (Sigma-Aldrich)] [34]. Two to four 
samples were pooled together for a total protein con-
tent of 2.5  mg. Tissue lysates were passed through a 
column of layered inhibitor-conjugated beads con-
sisting of sepharose-conjugated Shokat, AGCbead 
(UNC-21474), Purvalanol B, PP58, VI-16832 and CTx-
0294885 (Fig.  5a) [34]. Kinase-bound inhibitor beads 
were washed eluted, reduced, alkylated, and concen-
trated before chloroform/methanol extraction. Protein 
pellets were resuspended in 50  mM HEPES (pH 8.0), 
digested, with trypsin (Promega), labeled with iTRAQ 
reagent (AB SCIEX, Framingham, MA) and cleaned 
with PepClean C18 spin columns (Thermo Scientific).
The details for mass spectrometry (MS) have been pre-
scribed previously [81]. Thermo Orbitrap Elite mass 
spectrometer with a nanoAquity UPLC system (Waters 
Corp.) was used for data acquisition. Briefly, peptides 
were first trapped in a 2 cm trapping column and sepa-
rated on a 20  cm column at room temperature. Sam-
ples were run in a full 200 min gradient. Spectra were 
searched against the Uniprot/Swiss-Prot database with 
Sequest HT on Proteome Discoverer software 1.4. Only 
peptides with high confidence were considered for 
quantitation.
Statistical analysis
Data are expressed as mean and standard error of the 
mean (SEM). Percentage of tumor-free mice amongst the 
diet groups was compared with Kaplan–Meier analyses. 
Log rank and Chi square test were used to investigate 
differences among groups for tumor latency. Continu-
ous variables for two groups were compared using Stu-
dent’s t-tests. Continuous variables for more than two 
groups were compared using one way analysis of vari-
ance (ANOVA) with Tukey’s post hoc test. The correla-
tion of latency with leptin level at different time points 
was computed via Spearman Rank correlation. Analyses 
were performed using SAS Version 9.3 (SAS Institute, 
Cary NC USA) or GraphPad Prism 5 software (GraphPad 
Software, Inc. La Jolla, CA, USA). P values <0.05 were 
considered statistically significant.
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Additional files
Additional file 1. Tumor burden and growth were not affected by diet. a. 
Tumor burden was quantified at sacrifice. b. Tumor volume was measured 
by calipers at detection and sacrifice. (N = 28 10 %; N = 31 60 %; N = 29, 
60–10 %).
Additional file 2. Measures of glucose intolerance were not altered by 
diet. A and b. Fasting and plasma insulin concentrations were measured 
in 6 h fasted mice at time points indicated. c. Homeostasis model assess-
ment of insulin resistance (HOMAIR) was calculated. (N = 12 10 %, N = 12 
60 %; N = 13 60–10 %).
Additional file 3. Kinome profiling revealed significant regulation of 
pathways by HFD that were reversed with weight loss. A and b. Quantita-
tive comparison of kinases in unaffected mammary tissues from mice 
using MIB/MS was conducted. Legend indicates three iTRAQ runs with 
2–4 samples pooled per group per run. The graphs indicates quantitative 
changes in kinase activity as a ratio of mice fed 60 % (a) or 60–10 % (b) diet 
relative to mice fed 10 % diet group. Ratio <1 denotes decreased kinase 
activity and >1 increased kinase activity. Kinase families are indicated (AGC: 
Containing PKA, PKG, PKC families; CAMK: Calcium/calmodulin-dependent 
protein kinase; CK1: Casein kinase 1; CMGC: Containing CDK, MAPK, GSK3, 
CLK families; STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; 
TK: Tyrosine kinase; TKL: Tyrosine kinase-like). c. Mean kinase activity is 
reported for mice fed 60 % diet (dark grey) or 60–10 % diet (light grey) 
compared to mice on 10 % diet group. Error bars are not indicated for clar-
ity. Statistically significant comparisons are reported in Fig. 5d.
Additional file 4. Kinome analysis revealed dramatic regulation of 
kinases by HFD and diet-induced weight loss. a. HFD (60 %-fed) mammary 
gland kinase activity of greater than 1.5 or less than 0.5 fold compared 
to 10 %-fed is presented. b. Weight loss (60–10 %-fed) mammary gland 
kinase activity of greater than 1.25 or less than 0.5 fold compared to 
10 %-fed is presented. In b, no error bar is present in pooled samples 
when kinases were down-regulated below level of detection and only 1 
run detected activity.
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